To receive the Femtech World newsletter, sign up here.
News
Mindset app launches ‘transformational’ therapy service as it gears up for expansion
Clementine users are now able to access one-to-one support alongside their hypnotherapy sessions
The mindset app Clementine has announced a “transformational” therapy service in a bid to encourage women to prioritise their mental wellbeing.
Clementine aims to help women manage stress, anxiety and poor sleep through cognitive hypnotherapy.
The app combines cognitive behavioural therapy, positive psychology and neuro-linguistic programming (NLP) with hypnotherapy, promising to boost women’s confidence and productivity.
Its new “Book a Therapist” service claims to “simplify” the process of choosing a therapist by allowing women to access one-to-one support alongside their hypnotherapy sessions.
“As women, a lot of the situations that we might be going through in life seem different, but in reality, what we are experiencing [as a result of those situations] is very similar. Whether you are a young girl who’s just finished school or a woman moving into her first job as a CEO, impostor syndrome and stress are the same, they just happen at different points,” founder and CEO, Kim Palmer, told Femtech World.
“With Clementine, we aim to foster a supportive community and provide the necessary resources to empower women to prioritise their mental health.”
The new therapy offering, which users can access on the app and on the Clementine website, stemmed from Palmer’s experience of seeking therapy following a mental health breakdown.
“One of the first things that I did when I was struggling with my mental health was seek support from a hypnotherapist,” the founder explained.
“At the time, my therapist created some sessions that I could access on my phone. But while the sessions were great, I realised that when you get stuck in our thoughts and feelings, an app will never be enough to dig you out. You need a bit more hand-holding.
“Through our new service, we aim to provide a holistic approach to mental wellness that combines the benefits of digital cognitive hypnotherapy with personalised, one-to-one support.”
With the rise of online therapy platforms, such as BetterHelp, Talkspace and Amwell, creating a solution that would help women navigate the often daunting landscape of therapy options was key, said Palmer.
“There are many therapy platforms out there, but we wanted to simplify the process by curating a select group of therapists whom we trust,” she said.
“We already work with these therapists and they already have sessions in the app, so people are more likely to feel like they already know them. Users can simply book a 30-minute complimentary call and, if they want to go ahead with the therapy, the therapist will provide them with a personalised plan tailored to their needs.”
Moving forward, Clementine is planning to expand its team of therapists in areas where additional support is needed and is working on a new feature that will allow users to add all the recorded therapy sessions to the app, Palmer said.
The company is preparing to launch a menstrual health partnership in the UK, Sweden, Mexico and Colombia, the founder also revealed.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






